ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC
Copyright © 2021. Published by Elsevier Inc..
The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation. This provides further evidence for the tailored use of VEGF/EGFR combinations.
| Errataetall: |
CommentOn: Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. - PMID 34388377 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Cancer cell - 39(2021), 9 vom: 13. Sept., Seite 1178-1180 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Le, Xiuning [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comment |
|---|
| Anmerkungen: |
Date Completed 24.12.2021 Date Revised 24.12.2021 published: Print-Electronic CommentOn: Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. - PMID 34388377 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ccell.2021.07.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329321498 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329321498 | ||
| 003 | DE-627 | ||
| 005 | 20231225204848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ccell.2021.07.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329321498 | ||
| 035 | |a (NLM)34388379 | ||
| 035 | |a (PII)S1535-6108(21)00396-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Le, Xiuning |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.12.2021 | ||
| 500 | |a Date Revised 24.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. - PMID 34388377 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Inc. | ||
| 520 | |a The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation. This provides further evidence for the tailored use of VEGF/EGFR combinations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a Erlotinib Hydrochloride |2 NLM | |
| 650 | 7 | |a DA87705X9K |2 NLM | |
| 650 | 7 | |a EGFR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Nilsson, Monique B |e verfasserin |4 aut | |
| 700 | 1 | |a Robichaux, Jacqulyne P |e verfasserin |4 aut | |
| 700 | 1 | |a Heymach, John V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer cell |d 2002 |g 39(2021), 9 vom: 13. Sept., Seite 1178-1180 |w (DE-627)NLM119589826 |x 1878-3686 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2021 |g number:9 |g day:13 |g month:09 |g pages:1178-1180 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ccell.2021.07.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2021 |e 9 |b 13 |c 09 |h 1178-1180 | ||